Recombinant Anti-APPBP1 antibody [EPR15732] (ab187142)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR15732] to APPBP1
- Suitable for: WB, Flow Cyt, IP
- Reacts with: Rat, Human
Overview
-
Product name
Anti-APPBP1 antibody [EPR15732]
See all APPBP1 primary antibodies -
Description
Rabbit monoclonal [EPR15732] to APPBP1 -
Host species
Rabbit -
Tested applications
Suitable for: WB, Flow Cyt, IPmore details -
Species reactivity
Reacts with: Rat, Human -
Immunogen
Synthetic peptide within Human APPBP1 aa 50-150. The exact sequence is proprietary.
Database link: Q13564 -
Positive control
- HeLa, A431, Human fetal muscle, Rat brain, Rat heart, Rat spleen and Human fetal brain lysates; HeLa cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR15732 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
-
Recombinant Protein
-
Related Products
Applications
Our Abpromise guarantee covers the use of ab187142 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | 1/1000 - 1/10000. Detects a band of approximately 60 kDa (predicted molecular weight: 60 kDa). | |
Flow Cyt | 1/120. ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
|
|
IP | 1/30 - 1/40. |
Target
-
Function
Regulatory subunit of the dimeric UBA3-NAE1 E1 enzyme. E1 activates NEDD8 by first adenylating its C-terminal glycine residue with ATP, thereafter linking this residue to the side chain of the catalytic cysteine, yielding a NEDD8-UBA3 thioester and free AMP. E1 finally transfers NEDD8 to the catalytic cysteine of UBE2M. Necessary for cell cycle progression through the S-M checkpoint. Overexpression of NAE1 causes apoptosis through deregulation of NEDD8 conjugation. -
Tissue specificity
Ubiquitous in fetal tissues. Expressed throughout the adult brain. -
Pathway
Protein modification; protein neddylation. -
Sequence similarities
Belongs to the ubiquitin-activating E1 family. ULA1 subfamily. -
Cellular localization
Cell membrane. Colocalizes with APP in lipid rafts. - Information by UniProt
-
Database links
- Entrez Gene: 8883 Human
- Entrez Gene: 84019 Rat
- Omim: 603385 Human
- SwissProt: Q13564 Human
- SwissProt: Q9Z1A5 Rat
- Unigene: 460978 Human
- Unigene: 4279 Rat
-
Alternative names
- 59 kDa antibody
- A 116A10.1 antibody
- Amyloid beta precursor protein binding protein 1 59kD antibody
see all
Images
-
All lanes : Anti-APPBP1 antibody [EPR15732] (ab187142) at 1/1000 dilution
Lane 1 : HeLa cell lysate
Lane 2 : A431 cell lysate
Lane 3 : Human fetal muscle tissue lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 60 kDa -
Flow cytometric analysis of HeLa cells (2% paraformaldehyde-fixed) labeling APPBP1 with ab187142 at 1/120 dilution (red) or a rabbit IgG (negative) (green), followed by Goat anti rabbit IgG (FITC) secondary at 1/150 dilution.
-
Western blot analysis of immunoprecipitation pellet from Human fetal brain lysate immunoprecipitated using ab187142 at 1/50 dilution (lane 1) or PBS control (lane 2).
Secondary: Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1500 dilution. -
All lanes : Anti-APPBP1 antibody [EPR15732] (ab187142) at 1/1000 dilution
Lane 1 : Rat brain tissue lysate
Lane 2 : Rat heart tissue lysate
Lane 3 : Rat spleen tissue lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 60 kDa
Protocols
Datasheets and documents
Certificate of Compliance
References (1)
ab187142 has been referenced in 1 publication.
- Zeng Y et al. An overactive neddylation pathway serves as a therapeutic target and MLN4924 enhances the anticancer activity of cisplatin in pancreatic cancer. Oncol Lett 18:2724-2732 (2019). PubMed: 31404297